External Innovation Partner, Oncology Research Intelligence (Targeted Protein Degradation & Induced Proximity)

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at Astellas.com.

We're seeking passionate individuals who thrive in dynamic environments, embrace new ideas, and aren't afraid to take intelligent risks. People who act with unwavering integrity and are deeply committed to making a tangible impact.

The External Innovation Partner, Oncology Research - Targeted Protein Degradation & Induced Proximity is a scientific leadership role that serves as an External Catalyst, connecting Astellas Oncology Research with leading external innovation ecosystems in targeted protein degradation, induced proximity, and degrader-conjugate science.

Reporting to the Head of CI & RPM, this role proactively identifies, evaluates, and shapes external opportunities across PROTACs, molecular glues, monovalent/direct degraders, degrader platforms, E3/UPS biology including CRBN, VHL, and novel E3 ligases, target engagement, proteomics/chemoproteomics, structural and computational degrader design, Degrader Antibody Conjugates (DACs), next-generation induced-proximity technologies such as RIPTAC and TCIP, and other oncology-relevant targeted-delivery or induced-proximity modalities.

The role translates external scientific signals into research hypotheses, differentiation logic, critical-assumption questions, and scientific assessments that guide research strategy and support BD-led partnership discussions in close collaboration with internal research leaders.

• Build trusted access to academic investigators, KOLs/KEEs, biotech founders, incubators, investors, CROs, tech-transfer offices, venture creation groups, and scientific consortia focused on TPD, induced proximity, oncology chemical biology, proteomics, and degrader-conjugate science.
• Prioritize engagement with leading innovation ecosystems and global centers of excellence in degrader science, induced proximity, oncology research, chemical proteomics, and DAC/degrader-conjugate technologies.
• Represent Astellas Oncology Research at major scientific conferences, innovation forums, targeted partnering events, and academic meetings to uncover early-stage opportunities before they become broadly visible.
• Actively track scientific and company activity across PROTACs, molecular glues, monovalent/direct degraders, novel E3 ligase recruiters, CRBN/VHL biology, target engagement, proteomics/chemoproteomics, next-generation induced-proximity technologies such as RIPTAC and TCIP, and DACs.
• Maintain dynamic hub heatmaps, KEE maps, company/platform landscapes, and opportunity pipelines that enable rapid triage and high-quality internal decision-making.

• Identify high-impact external science, platform technologies, targets, mechanisms, and translational capabilities with potential relevance to Astellas oncology research priorities and future portfolio options.
• Assess TPD and induced-proximity opportunities based on target biology, degradability, modality fit, E3/UPS strategy, mechanism of action, target engagement, proteomic selectivity, cellular pharmacology, DMPK/PK-PD, differentiation, competitive positioning, and development risk.
• Evaluate platform-partnership opportunities for scientific maturity, scalability, target-ligase knowledge, assay/model access, reproducibility, IP/FTO considerations, and potential to unlock difficult-to-drug or previously inaccessible oncology targets.
• For DAC or degrader-conjugate opportunities, assess tumor antigen selection, internalization/trafficking biology, targeting vehicle properties, linker-payload strategy, degrader payload mechanism, degradation readouts, tumor selectivity, safety liabilities, and fit with Astellas capabilities.
• Translate early-stage innovation signals into strategic insights that support research prioritization, portfolio planning, and exploratory evaluation of external opportunities.

• Collaborate closely with Research Strategy Leads, Modality Intelligence Leads, Innovation Intelligence Analysts, and other subject-matter experts to ensure insights are shared and acted upon.
• Support BD-led opportunity evaluation in collaboration with Business Development and relevant embedded partners by providing scientific framing, diligence questions, data-package interpretation, and strategic context. Business Development retains accountability for partnership strategy, business discussions, negotiation, valuation, and commercial terms.
• Contribute to the development of intelligence infrastructure and best practices for horizon scanning, opportunity mapping, and external engagement across CI & RPM

• Advanced degree (PhD, MD, MBA, or equivalent) in Oncology, Life Sciences, or a related field.
• Minimum 8 years of experience in pharmaceutical R&D, external innovation, academic collaboration, or scientific partnering.
• Strong understanding of oncology drug discovery, translational science, and modality platforms (e.g., next gen ADCs, engineered biologics, engineered small molecules).
• Proven ability to engage with scientific leaders and navigate early-stage biotech and academic ecosystems.
• Excellent communication skills with the ability to synthesize complex scientific information into strategic insights.
• Prior experience in academic liaison, external innovation, or strategic scouting in pharma/biotech or venture ecosystems.
• Familiarity with CI platforms, digital literature monitoring tools, and academic/biotech databases.
• A strong network in academia or biotech focused on oncology.
• Experience in competitive intelligence, scientific scouting, or innovation strategy within oncology.
• Familiarity with academic-industry collaboration models and consortia-based innovation.
• High digital literacy and comfort with landscape analytics, scientific intelligence platforms, and conference tracking tools.

This position is based in Cambridge, MA or San Francisco, CA.  Remote work from anywhere in the US is available.

At Astellas we recognize the importance of work/life balance, and we are proud to offer a hybrid working solution allowing time to connect with colleagues at the office with the flexibility to also work from home. We believe this will optimize the most productive work environment for all employees to succeed and deliver. Hybrid work from certain locations may be permitted in accordance with Astellas’ Responsible Flexibility Guidelines.

• Global collaboration: Become part of a connected global business of like-minded life science leaders, all dedicated to improving patients' lives worldwide. Real-world patient impact: Contribute to transformative therapies that reach patients around the world, knowing your work makes a difference every day.
• Relentless Innovation: Join a company at the forefront of scientific breakthroughs, where you'll have the opportunity to shape the future of healthcare.
• A Culture of Growth: Chart your own course within a supportive environment that values your contributions, champions your development, and empowers you to pursue your passions.

$170,450 - $243,500 (Final compensation will be determined based on a variety of factors, including but not limited to skills, experience and organizational equity considerations)